Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00842283 · ClinicalTrials.gov registry record
Role of Angiogenesis in Dermatologic Diseases: A Potential Therapeutic Target
A clinical trial of Dermatologic Diseases, sponsored by University of California, Irvine.
- Recruiting
- Registry status
- 85
- Enrollment target
- 2
- Study locations
NCT00842283: Recruiting study of Dermatologic Diseases, sponsored by University of California, Irvine.
NCT00842283 is a study of Dermatologic Diseases that is actively recruiting participants, run by University of California, Irvine. The registered enrollment target is 85 participants. The trial reports 2 study locations across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00842283, a study of Dermatologic Diseases, is actively recruiting participants, sponsored by University of California, Irvine.
- RECRUITING
- Registry status
- 85 participants
- Enrollment target
- 2
- Study locations
Study Summary
The researchers believe that pro-angiogenic factors are upregulated in a wide range of dermatologic diseases, including port wine stains, hemangiomas, angiofibromas, Kaposi's sarcoma, angiosarcoma, scars, rosacea, and psoriasis. Select specimens may undergo genetic analysis to investigate underlying molecular pathways associated with dysregulated angiogenesis in cutaneous disease. Biospecimens, either previously obtained or newly collected from dermatologic conditions, will be analyzed for angiogenic markers. Discarded skin tissue from surgical or biopsy procedures may also be used, including both diseased and non-diseased tissue from the same donor. Some specimens may also undergo genetic analysis to investigate underlying molecular pathways. De-identified data such as age, sex, race, cause of death, lesion location, and description will be recorded. Currently, specimens are limited to clinically diagnosed lesions not typically biopsied, or lesions already confirmed by prior biopsy.
Primary Outcome
Evaluate the role of angiogenesis in cutaneous disease and ultimately, facilitate implementation of anti-angiogenic therapy in a wide range of dermatologic diseases including port wine stains, hemangiomas, angiofibromas, Kaposi's sarcoma, angiosarcoma, scars, rosacea and psoriasis.
Conditions Studied
Interventions
- OTHER skin tissue sample
Study Locations (2)
California
- Beckman Laser Institute and Medical Clinic - Irvine
- Dermatology Clinic at Gavin Herbert Eye Institute - Irvine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 85 participants |
| Start Date | 2008-11 |
| Est. Completion | 2026-12 |
What NCT00842283 shows while recruiting
NCT00842283 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 85 participants, a relatively small participant target.
The record links to 1 condition, with Dermatologic Diseases appearing as the primary indexed condition, and to 1 intervention - of which skin tissue sample is the first listed.
NCT00842283 reports a single indexed study location in California.
Frequently Asked Questions
What is clinical trial NCT00842283 about?
NCT00842283 is a clinical study titled "Role of Angiogenesis in Dermatologic Diseases: A Potential Therapeutic Target". The researchers believe that pro-angiogenic factors are upregulated in a wide range of dermatologic diseases, including port wine stains, hemangiomas, angiofibromas, Kaposi's sarcoma, angiosarcoma, scars, rosacea, and psoriasis. Select specimens may undergo genetic analysis to investigate underlying...
What is the current status of trial NCT00842283?
This trial is currently recruiting. The enrollment target is 85 participants. The study started on 2008-11. Estimated completion is 2026-12.
What conditions does trial NCT00842283 study?
This clinical trial studies the following conditions: Dermatologic Diseases.
What interventions are being tested in trial NCT00842283?
The interventions under investigation include: skin tissue sample (OTHER).
Who is sponsoring clinical trial NCT00842283?
This trial is sponsored by University of California, Irvine, which has 368 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00842283 being conducted?
This trial has 2 study locations across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02133196 · 85 participants · Phase 2
T Cell Receptor Immunotherapy for Patients With Metastatic Non-Small Cell Lung Cancer
- NCT03823144 · 85 participants · NA
Intravital Microscopy in Human Solid Tumors
- NCT03875638 · 85 participants · Phase 2
Treating Hyperexcitability in AD With Levetiracetam
- NCT03896529 · 85 participants · NA
Neurobiological Mechanisms of Aging and Stress on Prospective Navigation
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia